Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer
JCO Precision Oncology · 2025
DOI: 10.1200/po-25-00574 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Abhishek Ajay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, and Case Western Reserve University, Clevela…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy associated with an exceptionally poor prognosis. A limitation in its standard-of-care management is the absence of practical molecular tools for monitoring disease progression. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with potential applications in prognostication, early detection of cancer recurrence, refined evaluation of treatment response, and improved disease surveillance. MATERIALS AND METHODS We analyzed serial plasma samples from 81 patients with SCLC using a 105-gene hybrid capture-based next-generation sequencing liquid biopsy assay at three key time points: diagnosis, postchemotherapy, and clinical relapse. RESULTS Extensive-stage (ES) patients demonstrated significantly higher median baseline maximum variant allele frequency (VAF max ) compared with limited-stage cases. Notably, limited-stage patients with VAF max >40% experienced outcomes similar to those with ES disease. Across the cohort, median VAF max values declined from 53.30% at baseline to 0.15% during remission and then rose to 38.65% at relapse, reflecting initial therapeutic sensitivity followed by disease recurrence that remained unremitting. Baseline VAF max correlated with the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Moreover, disease-free survival (DFS), defined as the time to relapse from the date of clinical response (evaluated post–4-cycle chemotherapy), was significantly associated with baseline VAF max and a decline in VAF max of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, and Case Western Reserve University, Cleveland, OH.
- Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, OH.
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine/University Hospitals, Cleveland Medical Center, Cleveland, OH.
ORCID-Profile: Abhishek Ajay, Ali Rezvani, Zhengyi Chen, Gary M Wildey, Pingfu Fu, Afshin Dowlati
Förderung
- NCI NIH HHS
Zitieren
APA
Ajay, A., Ferdousi, R., Joseph, P. L., Durer, S., Rezvani, A., Chen, Z., Wildey, G. M., Lam, M., Fu, P., & Dowlati, A. (2025). Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00574
Vancouver
Ajay A, Ferdousi R, Joseph PL, Durer S, Rezvani A, Chen Z, et al. Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-25-00574
BibTeX
@article{Ajay2025,
author = {Ajay, Abhishek and Ferdousi, Reza and Joseph, Peronne L and Durer, Seren and Rezvani, Ali and Chen, Zhengyi and Wildey, Gary M and Lam, Minh and Fu, Pingfu and Dowlati, Afshin},
title = {Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung Cancer},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-25-00574}
}
EUVIMED